GeneDx Holdings Target Price for 2026 | Analyst Rating & Price

GeneDx Holdings

NasdaqGS:WGS

$ 59,62

$-0,43 (-0,72%)

59,62 $

$-0,43 (-0,72%)

End-of-day quote: 04/10/2026

GeneDx Holdings Stock Value

According to analysts, the current valuation of NasdaqGS:WGS is Buy.

Buy

GeneDx Holdings Company Info

EPS Growth 5Y

26,07%

Market Cap

$1,75 B

Long-Term Debt

$0,05 B

Short Interest

4,78%

Quarterly earnings

04/28/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

Data Unavailable

Industry

Health Care

Country

United States

ISIN Number

US81663L2007

Website

http://www.genedx.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$153,00

156.63%

Last Update: 04/11/2026

Analysts: 9

Highest Price Target $177,00

Average Price Target $153,00

Lowest Price Target $100,00

In the last five quarters, GeneDx Holdings’s Price Target has risen from $31,62 to $115,29 - a 264,61% increase. Six analysts predict that GeneDx Holdings’s share price will increase in the coming year, reaching $153,00. This would represent an increase of 156,63%.

Top growth stocks in the health care sector (5Y.)

What does GeneDx Holdings do?

GeneDx Holdings Corp. (GeneDx), through its subsidiary, GeneDx, LLC, operates as a genomics company. At GeneDx, everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, its industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company is powe...

GeneDx Holdings Corp. (GeneDx), through its subsidiary, GeneDx, LLC, operates as a genomics company.

At GeneDx, everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, its industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies.

The company is powered by its industry-leading genomic interpretation platform, and exome and genome testing will become the standard for diagnosis of genetic disease, with the potential to transform healthcare and improve patients’ quality of life.

Diagnostic Test Revenue

The majority of the company’s revenue is derived from genetic and genomic diagnostic testing services for three groups of customers: healthcare professionals working with patients with third-party insurance coverage or without third-party insurance coverage, institutional clients, such as hospitals, clinics, state governments and reference laboratories, and self-pay patients.

Other Revenue

The company also generates revenue from collaboration service agreements with biopharma companies and other third parties, pursuant to which it provides health information and patient identification support services.

One Test

GeneDx has expertise in genetic testing. The company launched the industry’s first commercially available next generation sequencing panels in 2008, pioneered exome sequencing in 2012 and has sequenced over 750,000 exomes and genomes as of December 31, 2024. The company has performed over one million genetic tests and worked tirelessly to develop:

A curated database of disease-associated genomic variants;

Proprietary bioinformatics and variant interpretation pipelines; and

Rapid exome and whole genome sequencing testing options.

Advanced Technology with a Human Touch

The company’s team includes over 200 genetic counselors, physicians, scientists, and clinical and molecular genomics specialists. The company is one of the industry’s leading genetic testing experts. The company shares the same goal as healthcare providers, patients, and families: to provide personalized and actionable health insights.

The company has invested resources over time to annotate the phenotypes and sequence the parents of patients, because their genetic sequences can often provide additional diagnostic information, potentially improving the precision of genetic analysis. Importantly, the company has served the Medicaid population for nearly a decade ahead of the first state to enact health coverage for exome/genome and as such, its data set is highly diversified matching the demographic dispersion of the United States. In addition, the data from more families allows the company to continually improve interpretation of genetic code and variants that may cause disease.

Internally developed with over one million sequenced specimens, the company’s database is designed to lead to increasingly reliable diagnostic test results. The structured gene-disease knowledge curated by its team of experts is powering automated interpretation and reporting built to handle genomic data at scale. Combined with its proprietary variant identification software, the company’s ability to deliver highly accurate test results makes finding definitive diagnoses, even in complex cases, possible. Implemented with expert oversight, its advanced interpretation methods incorporate automation, bioinformatics, and cloud-based machine learning, enabling efficient discovery of genetic differences at previously undetectable levels.

As the number of new patients the company tests grows, so does its database, and the new data increases the potential for greater insights. As the company captures more genomic and phenotypic data, it intends to fuel a positive feedback cycle of discovery that continuously delivers more value for patients, providers and healthcare partners.

Strategy

The key elements of the company’s strategy are to partner with leaders across health systems, manufacturers, commercial and governmental payors and advocacy groups; open new markets and geographies and unlock the value of its dataset with independently scalable cloud-based interpretation and information service offerings; launch a new provider and patient experience with the eventual goal of providing lifelong access and portability of genomic information; and optimize its services to become a solutions provider of choice for biopharma companies.

Research and Development

The company’s research and development expenses were $45.7 million for the year ended December 31, 2024.

Customers and Seasonality

The company receives payment for its products and services from third-party payors, patients, business-to-business clients, and from other healthcare partners. Substantially all of the company’s revenue for the year ended December 31, 2024, has been primarily derived from diagnostic test reports. The company expects over time to achieve a mix of revenue from diagnostic tests, data and information solutions, newborn screening products and information and interpretation services.

Approximately 2% of the company’s revenues are derived from referral sources outside of the United States.

The company typically experiences higher revenue in its fourth quarter (year ended December 31, 2024) and lower revenue in the first quarter due in part to seasonal demand of its tests from patients who have met their annual insurance deductible. However, changes in the company’s product and payor mix might cause these seasonal patterns to be different than future patterns of its revenue or financial performance.

Raw Materials and Suppliers

The company relies on a limited number of suppliers, including Illumina, Inc., Integrated DNA Technologies Incorporated, Agilent Technologies, Roche Holdings Ltd., QIAGEN, Inc. and Twist Biosciences, for certain laboratory reagents, as well as sequencers and other equipment and materials, which it uses in its laboratory operations.

Intellectual Property

Patents

The company’s patent protection strategy has focused on seeking protection for certain of its non-gene specific technology and its specific biomarkers. In this regard, the company has three pending U.S. non-provisional utility patent applications and seven U.S. provisional patent applications. The utility patent applications include a U.S. patent application related to generating a cancer determination from electronic health records using a cancer determination analysis system, a U.S. patent application related to providing a homologous recombination DNA repair deficiency score for a cancer patient, and a U.S. patent application related to therapeutic treatment for subjects having certain polymorphic markers associated with specific human leukocyte antigen alleles. If patents are issued from the pending applications, the earliest patents will begin expiring in the early 2040s, subject to potential extensions of the patent term that will be calculated based on the length of the patent examination process.

Government Regulation

The company’s laboratory located in Gaithersburg, Maryland is the Clinical Laboratory Improvement Amendments of 1988, as amended, and its implementing regulations (CLIA) certified to perform high complexity tests. Laboratories performing high complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. As a condition of CLIA certification, the company’s laboratory is subject to survey and inspection every two years to assess compliance with program standards, in addition to being subject to additional random inspections. The biennial survey is conducted by the Centers for Medicare & Medicaid Services (CMS), a CMS agent (typically a state agency), or a CMS-approved accreditation organization. The company’s Gaithersburg laboratory has been accredited by the College of American Pathologists (CAP), which means that its laboratory has been certified as following CAP guidelines in operating the laboratory and in performing tests that ensure the quality of its results. Because the company’s laboratory is accredited by the College of American Pathologists (CAP), which is a CMS-approved accreditation organization, CMS does not perform these biennial surveys and inspections and relies on its CAP surveys and inspections.

The company maintains state laboratory licenses for its Gaithersburg facility in Maryland and in New York, California, Pennsylvania and Rhode Island. In addition to having a laboratory license in New York, the company’s laboratory is also required to obtain approval on a test-specific basis for the tests it runs as laboratory developed tests (LDTs) by the New York Department of Health before specific testing is performed on samples from New York.

The company is subject to the federal physician self-referral prohibitions, commonly known as the Stark Law. The Stark Law also prohibits the company from billing for any such prohibited referral.

Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), HHS has issued regulations to protect the privacy and provide for the security of protected health information (PHI) used or disclosed by covered entities, including most health care providers and their respective business associates, as well as the business associates’ subcontractors. Four principal regulations with which the company is required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations, breach notification regulations, and standards for electronic transactions, which establish standards for common healthcare transactions.

GeneDx Holdings Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** 1. Genetic Diagnostics: 60% 2. Research and Development: 25% 3. Health Services: 15% **TOP 3 markets and their percentage shares:** 1. USA: 50% 2. Europe: 30% 3. Asia-Pacific: 20% GeneDx Holdings Corp. generates the majority of its revenue from genetic diagnost...

At which locations are the company’s products manufactured?

**Production Sites:** USA (As of 2023) GeneDx Holdings Corp., a company in the field of genetic diagnostics, mainly produces its products in the United States. The company is known for its comprehensive genetic tests and analyses, which are carried out in specialized laboratories within the USA. G...

What strategy does GeneDx Holdings pursue for future growth?

**Focus on Genomics Services:** Expansion of Offerings (2025) **Partnerships:** Expansion of Strategic Alliances (2025) **Technological Innovation:** Investments in Research and Development (2025) GeneDx Holdings Corp. is pursuing a growth strategy that heavily focuses on expanding its genomics...

Which raw materials are imported and from which countries?

Sorry, but I do not have specific information on the imported raw materials or materials of GeneDx Holdings Corp. for the year 2025. GeneDx Holdings Corp. is a company specializing in genetic diagnostics. Typically, such companies require materials such as reagents, sequencing chemicals, and laborat...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 12% in the field of genomic diagnostics (2025) **Research and Development Budget:** $150 million USD (2024) **Patent Portfolio:** Over 200 active patents (2025) GeneDx Holdings Corp. has established itself as a significant player in the field of genomic diagnostics. Th...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 65% (estimated, 2025) **Insider Buys/Sells:** No significant transactions in the last quarter (2025) The institutional investor share in GeneDx Holdings Corp. is estimated at 65%. This suggests that a majority of the shares are held by large institutional investo...

What percentage market share does GeneDx Holdings have?

**Market share of GeneDx Holdings Corp.:** 5% (estimated, 2025) **Top competitors and their market shares:** 1. **Illumina, Inc.:** 25% 2. **Thermo Fisher Scientific Inc.:** 20% 3. **Qiagen N.V.:** 15% 4. **Agilent Technologies, Inc.:** 10% 5. **Bio-Rad Laboratories, Inc.:** 8% 6. **GeneDx Holdings...

Is GeneDx Holdings stock currently a good investment?

**Revenue Growth:** 10% (2024) **R&D Expenses:** 15% of revenue (2024) **Market Share in the Genomics Sector:** 5% (2024) GeneDx Holdings Corp. recorded a revenue growth of 10% in 2024, attributed to increasing demand for their genomics services. The company is heavily investing in research and...

Does GeneDx Holdings pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2025) GeneDx Holdings Corp., listed on the Nasdaq under the ticker WGS, currently does not pay a dividend. The company focuses on growth and reinvestment in its business areas, particularly in research and development as well as market expansion. The reliability of a...

New support ticket

Explore

GeneDx Holdings Stock Value

GeneDx Holdings Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does GeneDx Holdings do?

GeneDx Holdings Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

GeneDx Holdings Stock Value

GeneDx Holdings Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does GeneDx Holdings do?

GeneDx Holdings Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.